Indotecan

Drug Profile

Indotecan

Alternative Names: LMP-400; NSC-724998; NSC-743400

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); Purdue University
  • Developer National Cancer Institute (USA)
  • Class Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 02 Jun 2017 Safety and efficacy data from a phase I trial in Solid tumours and Lymphomas presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top